IRIS
LAPADULA, Giovanni
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 15.334
AS - Asia 5.391
EU - Europa 3.832
SA - Sud America 1.538
AF - Africa 197
Continente sconosciuto - Info sul continente non disponibili 10
OC - Oceania 9
Totale 26.311
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 15.164
SG - Singapore 2.322
CN - Cina 1.245
BR - Brasile 1.206
SE - Svezia 714
HK - Hong Kong 672
FR - Francia 660
RU - Federazione Russa 527
DE - Germania 482
VN - Vietnam 375
IT - Italia 369
FI - Finlandia 312
GB - Regno Unito 262
UA - Ucraina 195
IN - India 166
AR - Argentina 127
BD - Bangladesh 112
IQ - Iraq 86
CA - Canada 68
BE - Belgio 62
MX - Messico 58
ID - Indonesia 55
IE - Irlanda 51
PK - Pakistan 51
ZA - Sudafrica 51
TR - Turchia 49
EC - Ecuador 45
CO - Colombia 43
SA - Arabia Saudita 36
JP - Giappone 34
VE - Venezuela 33
ES - Italia 32
MA - Marocco 30
CI - Costa d'Avorio 27
PL - Polonia 25
UZ - Uzbekistan 24
NL - Olanda 23
PY - Paraguay 23
CL - Cile 22
AT - Austria 21
EG - Egitto 21
PH - Filippine 21
IR - Iran 18
TN - Tunisia 18
CZ - Repubblica Ceca 16
LT - Lituania 16
AZ - Azerbaigian 15
JM - Giamaica 13
PE - Perù 13
KE - Kenya 12
UY - Uruguay 12
NP - Nepal 10
AE - Emirati Arabi Uniti 9
BO - Bolivia 9
DZ - Algeria 9
ET - Etiopia 9
JO - Giordania 9
MY - Malesia 9
EU - Europa 8
OM - Oman 8
DK - Danimarca 7
AL - Albania 6
AU - Australia 6
IL - Israele 6
RS - Serbia 6
TH - Thailandia 6
BY - Bielorussia 5
CH - Svizzera 5
CR - Costa Rica 5
HN - Honduras 5
HR - Croazia 5
KG - Kirghizistan 5
KZ - Kazakistan 5
LB - Libano 5
NI - Nicaragua 5
PA - Panama 5
QA - Qatar 5
RO - Romania 5
AO - Angola 4
BG - Bulgaria 4
DO - Repubblica Dominicana 4
HU - Ungheria 4
MD - Moldavia 4
MN - Mongolia 4
PS - Palestinian Territory 4
SY - Repubblica araba siriana 4
BH - Bahrain 3
GE - Georgia 3
GF - Guiana Francese 3
GR - Grecia 3
KR - Corea 3
SK - Slovacchia (Repubblica Slovacca) 3
SN - Senegal 3
AM - Armenia 2
DM - Dominica 2
EE - Estonia 2
GY - Guiana 2
LA - Repubblica Popolare Democratica del Laos 2
MU - Mauritius 2
TT - Trinidad e Tobago 2
Totale 26.278
Salva come PNG Salva come JPEG
Città #
Fairfield 1.879
Woodbridge 1.473
Ashburn 1.376
Singapore 1.258
Houston 1.192
Chandler 1.067
Seattle 798
Ann Arbor 748
Cambridge 683
Hong Kong 668
San Jose 640
Wilmington 607
Nyköping 550
Jacksonville 539
Beijing 356
Lawrence 245
Roxbury 245
Nanjing 225
Lauterbourg 222
Dallas 220
New York 194
Des Moines 149
Inglewood 145
Los Angeles 136
Princeton 136
Ho Chi Minh City 111
Munich 108
São Paulo 103
Boardman 96
Bari 94
Santa Clara 93
San Diego 86
Helsinki 84
Dearborn 81
Hanoi 78
London 70
Shenyang 65
Brussels 62
Moscow 62
Brooklyn 59
Paris 54
Buffalo 51
Dublin 50
Hebei 50
Nanchang 44
Turku 42
Council Bluffs 41
Rio de Janeiro 41
Jiaxing 39
Baghdad 38
Chicago 35
Redwood City 35
Changsha 32
Frankfurt am Main 32
Tokyo 32
Belo Horizonte 31
The Dalles 31
Tianjin 31
Boston 28
Jakarta 28
Columbus 27
San Francisco 27
Abidjan 26
Falkenstein 26
Nuremberg 26
Brasília 23
Dong Ket 23
Guangzhou 23
Lahore 23
Orem 23
Tashkent 23
Toronto 23
Warsaw 23
Montreal 21
Denver 20
Dhaka 20
Johannesburg 20
Campinas 19
Atlanta 18
Da Nang 18
Hefei 18
Chennai 17
Poplar 17
Quito 17
Augusta 16
Guayaquil 16
Jinan 16
Mumbai 16
Jeddah 15
Shanghai 15
Stockholm 15
Baku 14
Haiphong 14
New Delhi 14
Vienna 14
Istanbul 13
Kunming 13
Manchester 13
Mexico City 13
Pune 13
Totale 18.519
Salva come PNG Salva come JPEG
Nome #
Sarcopenia in Patients with Rheumatic Diseases: Prevalence and Associated Risk Factors 201
Safety of Long-Term Biologic Therapy in Rheumatologic Patients With a Previously Resolved Hepatitis B Viral Infection 200
No changes in N-terminal pro-brain natriuretic peptide in a longitudinal cohort of patients with systemic sclerosis-associated pulmonary arterial hypertension on therapy with bosentan 190
AB0836 Drug retention rate of the first tnf inhibitor in radiographic and non radiographic axial spondyloarthritis: data from a multicenter study 187
Correlation between serum amyloid-A and serum levels of proinflammatory cytokines in patients with Behçet's disease 185
AB0065 Possible Interplay Between Serum Amyloid-A and Pro-Inflammatory Cytokines Into the Pathogenesis of Behçet's Disease 183
A Case of Osteonecrosis of the Jaw in a Patient with Crohn's Disease Treated with Infliximab 179
AB0452 Changes in Lipoproteins Associated with Tocilizumab Treatment Do not Influence the Atherogenic Index of Plasma of Rheumatoid Arthritis Patients: Table 1 175
AB0618 A unique ultrasound pattern of adipose tissue in systemic sclerosis patients: a comparison with rheumatoid arthritis patients and healthy controls. two sides of adipose tissue involvement in systemic chronic inflammatory diseases 172
Adalimumab in the treatment of immune-mediated diseases 169
A false occult hepatitis B virus infection developed in a patient with psoriatic arthritis under infliximab and methotrexate therapy 169
Early changes of articular cartilage, synovial membrane and subchondral bone in an experimental model of goat osteoarthrtitis 167
Mucocutaneous Involvement in Behçet's Disease: How Systemic Treatment Has Changed in the Last Decades and Future Perspectives 167
Retinal vessels thrombosis as onset manifestation of systemic sclerosis: 3 clinical cases 165
Efficacy and safety profile of anti-interleukin-1 treatment in Behçet’s disease: a multicenter retrospective study 165
Obesity reduces the drug survival of second line biological drugs following a first TNF-α inhibitor in rheumatoid arthritis patients 165
AB0041 Serum Amyloid A Stimulates The Induction of Inflammatory Mediators in Monocytes from Behçet's Disease Patients: A Proof of Concept Study 164
Possible interplay between interleukin-15 and interleukin-17 into the pathogenesis of idiopathic inflammatory myopathies 163
Two-year survival rates of anti-TNF-α therapy in psoriatic arthritis (PsA) patients with either polyarticular or oligoarticular PsA 161
Interleukin-1 as a common denominator from autoinflammatory to autoimmune disorders: Premises, perils, and perspectives 161
Efficacy and safety of rituximab with and without methotrexate in the treatment of rheumatoid arthritis patients: Results from the GISEA register 160
Phenotypes Determined by Cluster Analysis and Their Survival in the Prospective European Scleroderma Trials and Research Cohort of Patients With Systemic Sclerosis 158
Papular-purpuric gloves and socks syndrome due to parvovirus B19: a report of two simultaneous cases in cohabitant families 156
Refractory knee giant cell tumor of the synovial membrane treated with intra-articular injection of Infliximab: A case series and review of the literature 155
SAT0216 Chest Ultrasound Signs of Interstitial Lung Disease in Systemic Sclerosis Patients: A Comparison between High Resolution Chest Computed Tomography Findings 153
Body mass does not affect the remission of psoriatic arthritis patients on anti-TNF-α therapy 152
Lipids and atherogenic indices fluctuation in rheumatoid arthritis patients on long-term tocilizumab treatment 152
Golimumab in real-life settings: 2 Years drug survival and predictors of clinical outcomes in rheumatoid arthritis, spondyloarthritis, and psoriatic arthritis 151
Different switching rate of anti-TNF-α drugs in monotherapy and in combination with methotrexate in a cohort of rheumatoid arthritis patients in the real life 150
Orofacial Manifestations and Temporomandibular Disorders of Sjogren Syndrome: An Observational Study 148
Lipid Profile of Rheumatoid Arthritis Patients Treated with Anti-Tumor Necrosis Factor-Alpha Drugs Changes According to Disease Activity and Predicts Clinical Response 147
A gender gap in primary and secondary heart dysfunctions in systemic sclerosis: A EUSTAR prospective study 147
Leucocytoclastic vasculitis as onset symptom of ulcerative colitis 146
Effectiveness and tuberculosis-related safety profile of interleukin-1 blocking agents in the management of Behçet's disease 146
Obesity and reduction of the response rate to anti-tumor necrosis factor α in rheumatoid arthritis: An approach to a personalized medicine 146
Old and new antirheumatic drugs and the risk of hepatotoxicity 146
AN UNWELCOME HOST IN THE PATHOGENESIS OF ARTHRITIDES 145
Orofacial Manifestations and Temporomandibular Disorders of Systemic Scleroderma: An Observational Study. 145
ANTI-TNFA THERAPY IN PSORIATIC ARTHRITIS: DIFFERENT RATE OF REMISSION IN POLYARTICULAR AND OLIGOARTICULAR SUBSETS 144
Paradoxical mucocutaneous flare in a case of Behçet’s disease treated with tocilizumab 143
THU0153 The effect of 5-years b-dmards treatment on different 10-years cardiovascular risk scores applied in rheumatoid arthritispatients 142
Update on laser-evoked potential findings in fibromyalgia patients in light of clinical and skin biopsy features 141
SAT0212 Pericardial Effusion Related To Systemic Sclerosis: A Possible Contribution of The Serum Levels of Adipokines and Interleukines 137
Intra-articular therapy with tumor necrosis factor-α antagonists: An update 136
Serum amyloid-A in Behçet's disease 136
LIPID PROFILE OF RHEUMATOID ARTHRITIS PATIENTS TREATED WITH ANTI-TNF-ALPHA DRUGS CHANGES ACCORDING TO DISEASE ACTIVITY RESPONSE 136
PFAPA syndrome and Behçet’s disease: a comparison of two medical entities based on the clinical interviews performed by three different specialists 135
ASSOCIATION OF SYSTEMIC SCLEROSIS AND PSORIATIC ARTHRITIS: A CASE REPORT 134
Analysis of subchondral cortical plate and trabecular bone in osteoarthritis experimentally induced in goat tibia. Preliminary results 134
Proinflammatory cytokines and antiskin autoantibodies in patients with inherited epidermolysis bullosa 134
FRI0110 Methotrexate monotherapy in real life: a drug survival analysis. comparison between very early arthritis and early arthritis cohorts 134
The profiling of axial spondyloarthritis patient candidate to a biologic therapy: Consensus from a Delphi-panel of Italian experts 133
Joint and tendon involvement predict disease progression in systemic sclerosis: A EUSTAR prospective study 133
Longterm clinical outcomes in 420 patients with psoriatic arthritis taking anti-tumor necrosis factor drugs in real-world settings 131
Untangling the web of systemic autoinflammatory diseases 131
PRESENT STATUS AND NEW PERSPECTIVES IN NON-STEROIDAL ANTI-INFLAMMATORY DRUGS THERAPY 130
Improvement of renal function and disappearance of hepatitis B virus DNA in a patient with rheumatoid arthritis and renal amyloidosis following treatment with infliximab 129
Safety of etanercept and methotrexate in patients with rheumatoid arthritis and hepatitis C virus infection: A multicenter randomized clinical trial 129
Red flags for appropriate referral to the gastroenterologist and the rheumatologist of patients with inflammatory bowel disease and spondyloarthritis 129
Serum cartilage oligomeric matrix protein (COMP) following infliximab treatment in patients with rheumatoid arthritis: Analitical performances and clinical correlations 129
Management of Small Vessel Vasculitides 128
High rate of disease remission in moderate rheumatoid arthritis on etanercept therapy: Data from GISEA, the Italian biologics register 127
Evaluation of Serum Levels of Adipokines and Interleukines in Pericardial Effusion Related to Systemic Sclerosis 127
Early-onset sarcoidosis caused by a rare CARD15/NOD2 de novo mutation and responsive to infliximab: a case report with long-term follow-up and review of the literature 126
AB0245 PREDICTORS OF BIOLOGIC THERAPY DISCONTINUATION IN RHEUMATOID ARTHRITIS PATIENTS AFTER REMISSION ACHIEVEMENT: A MONOCENTRIC OBSERVATIONAL STUDY FROM BIOLOGIC APULIAN REGISTRY (BIOPURE) 126
Bone and kidney toxicity induced by nucleotide analogues in patients affected by HBV-related chronic hepatitis: a longitudinal study. 125
Different joint and skin clinical response of patients with psoriatic arthritis treated with infliximab 125
The use of biosimilars in immune-mediated disease: A joint Italian Society of Rheumatology (SIR), Italian Society of Dermatology (SIDeMaST), and Italian Group of Inflammatory Bowel Disease (IG-IBD) position paper 124
OP0129 Drug survival on anti-tnf-alpha in psoriatic arthritis patients with axial involvement and analysis of predictors 124
). Analysis of subchondral cortical plate and trabecular bone in osteoarthritis experimentally induced in goat tibia. Preliminary results. 123
ISOLATED STERNOCLAVICULAR JOINT ARTHRITIS IN HEROIN ADDICTS AND/OR HIV POSITIVE PATIENTS: THREE CASES 123
Obesity and Inflammation – Targets for OA Therapy 122
Improvement of Refractory Dysphagia in Patients with Idiopathic Inflammatory Myopathies Receveing Immunoglobulin Intravenous Therapy 122
Diagnosis of latent tuberculosis and prevention of reactivation in rheumatic patients receiving biologic therapy: International recommendations 120
Drug survival on TNF inhibitors: 2003-2004 data from Italian National Register (GISEA Register) 119
Early clinical response predicts low disease activity at one year in rheumatoid arthritis patients on treatment with certolizumab in real-life settings. An appraisal of the Italian registry GISEA 119
Update on the profile of the EUSTAR cohort: An analysis of the EULAR Scleroderma Trials and Research group database 118
Long-term retention rate of anakinra in adult onset Still’s disease and predictive factors for treatment response 117
Anti-cyclic citrullinated peptide autoantibodies measured by an automated enzyme immunoassay: analytical performance and clinical correlations 117
Digital laser doppler flowmetry may discriminate "limited" from "diffuse" systemic sclerosis 116
The pathophysiology of osteoarthritis 116
Sarcoidosis presenting with Raynaud's syndrome: a case report 115
Prevalence of anti-CCP antibodies in systemic sclerosis 115
EULAR recommendations for the treatment of systemic sclerosis: A report from the EULAR Scleroderma Trials and Research group (EUSTAR) 114
Giant Cell Tumor of Synovial Sheath: Of Two Cases Treated with Intra-Articular Infiltration of Infliximab 114
THU0168 Relationships between body fat composition assessed with bioelectrical impedance analysis, serum adipokines and disease activity in patients with rheumatoid arthritis 114
Response of cartilage oligomeric matrix protein to monoclonal antibody drugs in patients with rheumatoid arthritis 114
Intentional etanercept use during pregnancy for maintenance of remission in rheumatoid arthritis 113
Efficacy and safety of certolizumab pegol in rheumatoid arthritis: Meeting rheumatologists' requirements in routine clinical practice 112
Drug survival and effectiveness of ustekinumab in patients with psoriatic arthritis. Real-life data from the biologic Apulian registry (BIOPURE) 112
Isolated thrombocytopenia associated with low dose methotrexate therapy 111
Intra-articular clodronate for the treatment of knee osteoarthritis: dose ranging study vs hyaluronic acid 110
PHENOTYPING OF CHONDROCYTES FROM HUMAN OSTEOARTHRITIC CARTILAGE: CHONDROCYTE EXPRESSION OF BETA INTEGRINS AND CORRELATION WITH ANATOMIC INJURY 110
GISEA: an Italian biological agents registry in rheumatology 110
A CASE OF SWEET'S SYNDROME WITH RHEUMATIC ONSET 109
Distribution of HLA-B27 subtypes in Sardinia and continental Italy and their association with spondylarthropathies 109
EARLY CHANGES OF ARTHICULAR CARTILAGE, SYNOVIAL MEMBRANE AND SUBCHONDRAL BONE IN AN EXPERIMENTAL MODEL OF GOAT OSTEOARTHRITIS 106
MONOCLONAL ANTIBODY INVESTIGATION IN RHEUMATOID ARTHRITIS: PRESENCE OF A T CELL SUBPOPULATION BEARING A DOUBLE MARKER 106
CHONDROCYTES-ECM INTERACTIONS IN HUMAN OSTEOARTHRITIS In: Mallia C., Uitto J. (eds) Rheumaderm. Advances in Experimental Medicine and Biology, vol 455. Springer, Boston, MA 106
THE INHIBITOR OF COSTIMULATION OF T CELLS: ABATACEPT 105
Totale 13.820
Salva come PNG Salva come JPEG
Categoria #
all - tutte 110.353
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 110.353
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021598 0 0 0 0 0 0 0 0 0 285 169 144
2021/20221.797 125 209 23 111 87 118 85 102 102 112 293 430
2022/20232.808 435 326 192 265 321 358 58 287 449 19 59 39
2023/2024758 77 174 32 55 49 176 17 43 3 33 12 87
2024/20253.723 63 65 342 103 56 311 275 391 165 216 576 1.160
2025/20266.914 1.138 384 472 969 918 454 944 271 716 648 0 0
Totale 26.970